Indicator type;Execution Sectors;Total
Units carrying out R&D in Biotechnology;Total;1,575
Units carrying out R&D in Biotechnology;Public Administration;116
Units carrying out R&D in Biotechnology;Higher Education;68
Units carrying out R&D in Biotechnology;Companies;1,376
Units carrying out R&D in Biotechnology;NPPI;15
% Units by type of biotechnology used: Genetic Code;Total;38.4
% Units by type of biotechnology used: Genetic Code;Public Administration;90.5
% Units by type of biotechnology used: Genetic Code;Higher Education;91.2
% Units by type of biotechnology used: Genetic Code;Companies;31.4
% Units by type of biotechnology used: Genetic Code;NPPI;33.3
% Units by type of biotechnology used: Functional Units;Total;48.9
% Units by type of biotechnology used: Functional Units;Public Administration;86.2
% Units by type of biotechnology used: Functional Units;Higher Education;91.2
% Units by type of biotechnology used: Functional Units;Companies;43.7
% Units by type of biotechnology used: Functional Units;NPPI;40.0
% Units by type of biotechnology used: Cell and Tissue Culture and Engineering;Total;28.8
% Units by type of biotechnology used: Cell and Tissue Culture and Engineering;Public Administration;67.2
% Units by type of biotechnology used: Cell and Tissue Culture and Engineering;Higher Education;80.9
% Units by type of biotechnology used: Cell and Tissue Culture and Engineering;Companies;22.8
% Units by type of biotechnology used: Cell and Tissue Culture and Engineering;NPPI;46.7
% Units by type of biotechnology used: Bioprocesses;Total;50.9
% Units by type of biotechnology used: Bioprocesses;Public Administration;59.5
% Units by type of biotechnology used: Bioprocesses;Higher Education;92.7
% Units by type of biotechnology used: Bioprocesses;Companies;48.3
% Units by type of biotechnology used: Bioprocesses;NPPI;33.3
% Units by type of biotechnology used: Subcellular Organisms;Total;13.8
% Units by type of biotechnology used: Subcellular Organisms;Public Administration;50.9
% Units by type of biotechnology used: Subcellular Organisms;Higher Education;67.7
% Units by type of biotechnology used: Subcellular Organisms;Companies;7.9
% Units by type of biotechnology used: Subcellular Organisms;NPPI;26.7
% Units by type of biotechnology used: Bioinformatics;Total;33.1
% Units by type of biotechnology used: Bioinformatics;Public Administration;73.3
% Units by type of biotechnology used: Bioinformatics;Higher Education;85.3
% Units by type of biotechnology used: Bioinformatics;Companies;27.1
% Units by type of biotechnology used: Bioinformatics;NPPI;33.3
% Units by type of biotechnology used: Nanobiotechnology;Total;16.9
% Units by type of biotechnology used: Nanobiotechnology;Public Administration;50.0
% Units by type of biotechnology used: Nanobiotechnology;Higher Education;75.0
% Units by type of biotechnology used: Nanobiotechnology;Companies;11.2
% Units by type of biotechnology used: Nanobiotechnology;NPPI;13.3
% Units by type of biotechnology used: Other;Total;16.5
% Units by type of biotechnology used: Other;Public Administration;7.8
% Units by type of biotechnology used: Other;Higher Education;8.8
% Units by type of biotechnology used: Other;Companies;17.6
% Units by type of biotechnology used: Other;NPPI;20.0
Units in which biotechnology activities are: Main and/or exclusive;Total;752
Units in which biotechnology activities are: Main and/or exclusive;Public Administration;27
Units in which biotechnology activities are: Main and/or exclusive;Higher Education;6
Units in which biotechnology activities are: Main and/or exclusive;Companies;711
Units in which biotechnology activities are: Main and/or exclusive;NPPI;8
Units in which biotechnology activities are: A secondary business line;Total;354
Units in which biotechnology activities are: A secondary business line;Public Administration;39
Units in which biotechnology activities are: A secondary business line;Higher Education;42
Units in which biotechnology activities are: A secondary business line;Companies;270
Units in which biotechnology activities are: A secondary business line;NPPI;3
Units in which biotechnology activities are: A necessary tool for production;Total;469
Units in which biotechnology activities are: A necessary tool for production;Public Administration;50
Units in which biotechnology activities are: A necessary tool for production;Higher Education;20
Units in which biotechnology activities are: A necessary tool for production;Companies;395
Units in which biotechnology activities are: A necessary tool for production;NPPI;4
% Units by final application areas of biotechnology use: Human Health;Total;52.3
% Units by final application areas of biotechnology use: Human Health;Public Administration;78.5
% Units by final application areas of biotechnology use: Human Health;Higher Education;92.7
% Units by final application areas of biotechnology use: Human Health;Companies;48.0
% Units by final application areas of biotechnology use: Human Health;NPPI;60.0
% Units by final application areas of biotechnology use: Animal Health and Aquaculture;Total;18.7
% Units by final application areas of biotechnology use: Animal Health and Aquaculture;Public Administration;18.1
% Units by final application areas of biotechnology use: Animal Health and Aquaculture;Higher Education;60.3
% Units by final application areas of biotechnology use: Animal Health and Aquaculture;Companies;16.9
% Units by final application areas of biotechnology use: Animal Health and Aquaculture;NPPI;6.7
% Units by final application areas of biotechnology use: Food Products;Total;31.1
% Units by final application areas of biotechnology use: Food Products;Public Administration;25.0
% Units by final application areas of biotechnology use: Food Products;Higher Education;80.9
% Units by final application areas of biotechnology use: Food Products;Companies;29.4
% Units by final application areas of biotechnology use: Food Products;NPPI;6.7
% Units by final application areas of biotechnology use: Agriculture and Forestry;Total;27.3
% Units by final application areas of biotechnology use: Agriculture and Forestry;Public Administration;22.4
% Units by final application areas of biotechnology use: Agriculture and Forestry;Higher Education;72.1
% Units by final application areas of biotechnology use: Agriculture and Forestry;Companies;25.7
% Units by final application areas of biotechnology use: Agriculture and Forestry;NPPI;13.3
% Units by final application areas of biotechnology use: Environment;Total;20.9
% Units by final application areas of biotechnology use: Environment;Public Administration;23.3
% Units by final application areas of biotechnology use: Environment;Higher Education;73.5
% Units by final application areas of biotechnology use: Environment;Companies;18.0
% Units by final application areas of biotechnology use: Environment;NPPI;26.7
% Units by final application areas of biotechnology use: Industry;Total;15.5
% Units by final application areas of biotechnology use: Industry;Public Administration;17.2
% Units by final application areas of biotechnology use: Industry;Higher Education;63.2
% Units by final application areas of biotechnology use: Industry;Companies;13.0
% Units by final application areas of biotechnology use: Industry;NPPI;6.7
R&D personnel in Biotechnology (PP);Total;49,624
R&D personnel in Biotechnology (PP);Public Administration;14,025
R&D personnel in Biotechnology (PP);Higher Education;18,065
R&D personnel in Biotechnology (PP);Companies;17,257
R&D personnel in Biotechnology (PP);NPPI;277
R&D personnel in Biotechnology (PP): Research personnel;Total;31,617
R&D personnel in Biotechnology (PP): Research personnel;Public Administration;8,400
R&D personnel in Biotechnology (PP): Research personnel;Higher Education;13,853
R&D personnel in Biotechnology (PP): Research personnel;Companies;9,195
R&D personnel in Biotechnology (PP): Research personnel;NPPI;169
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Total;18,006
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Public Administration;5,625
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Higher Education;4,212
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Companies;8,061
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;NPPI;108
R&D personnel in Biotechnology (PP). Women;Total;28,374
R&D personnel in Biotechnology (PP). Women;Public Administration;8,817
R&D personnel in Biotechnology (PP). Women;Higher Education;9,391
R&D personnel in Biotechnology (PP). Women;Companies;9,980
R&D personnel in Biotechnology (PP). Women;NPPI;186
R&D personnel in Biotechnology (PP). Women: Research personnel;Total;17,240
R&D personnel in Biotechnology (PP). Women: Research personnel;Public Administration;4,979
R&D personnel in Biotechnology (PP). Women: Research personnel;Higher Education;6,935
R&D personnel in Biotechnology (PP). Women: Research personnel;Companies;5,222
R&D personnel in Biotechnology (PP). Women: Research personnel;NPPI;104
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Total;11,134
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Public Administration;3,838
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Higher Education;2,456
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Companies;4,758
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;NPPI;82
R&D personnel in Biotechnology (FTE);Total;35,793.8
R&D personnel in Biotechnology (FTE);Public Administration;10,811.1
R&D personnel in Biotechnology (FTE);Higher Education;11,886.5
R&D personnel in Biotechnology (FTE);Companies;12,883.4
R&D personnel in Biotechnology (FTE);NPPI;212.8
R&D personnel in Biotechnology (FTE): Research personnel;Total;22,776.0
R&D personnel in Biotechnology (FTE): Research personnel;Public Administration;6,354.5
R&D personnel in Biotechnology (FTE): Research personnel;Higher Education;9,188.3
R&D personnel in Biotechnology (FTE): Research personnel;Companies;7,103.2
R&D personnel in Biotechnology (FTE): Research personnel;NPPI;130.0
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Total;13,017.8
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Public Administration;4,456.6
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Higher Education;2,698.2
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Companies;5,780.2
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;NPPI;82.8
R&D personnel in Biotechnology (FTE). Women;Total;20,951.5
R&D personnel in Biotechnology (FTE). Women;Public Administration;6,766.8
R&D personnel in Biotechnology (FTE). Women;Higher Education;6,436.5
R&D personnel in Biotechnology (FTE). Women;Companies;7,600.6
R&D personnel in Biotechnology (FTE). Women;NPPI;147.6
R&D personnel in Biotechnology (FTE). Women: Research personnel;Total;12,634.4
R&D personnel in Biotechnology (FTE). Women: Research personnel;Public Administration;3,729.2
R&D personnel in Biotechnology (FTE). Women: Research personnel;Higher Education;4,765.0
R&D personnel in Biotechnology (FTE). Women: Research personnel;Companies;4,057.0
R&D personnel in Biotechnology (FTE). Women: Research personnel;NPPI;83.2
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Total;8,317.2
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Public Administration;3,037.6
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Higher Education;1,671.5
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Companies;3,543.7
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;NPPI;64.4
Expenditure on internal R&D in Biotechnology (thousands of euros);Total;2,748,629
Expenditure on internal R&D in Biotechnology (thousands of euros);Public Administration;790,000
Expenditure on internal R&D in Biotechnology (thousands of euros);Higher Education;663,966
Expenditure on internal R&D in Biotechnology (thousands of euros);Companies;1,283,346
Expenditure on internal R&D in Biotechnology (thousands of euros);NPPI;11,317
1) By type of expenditure: Current expenditure;Total;2,534,791
1) By type of expenditure: Current expenditure;Public Administration;737,638
1) By type of expenditure: Current expenditure;Higher Education;606,138
1) By type of expenditure: Current expenditure;Companies;1,180,187
1) By type of expenditure: Current expenditure;NPPI;10,827
1.1) Labour expenditure of research personnel;Total;1,028,782
1.1) Labour expenditure of research personnel;Public Administration;268,921
1.1) Labour expenditure of research personnel;Higher Education;383,808
1.1) Labour expenditure of research personnel;Companies;372,421
1.1) Labour expenditure of research personnel;NPPI;3,632
1.2) Labour expenditure of technical and auxiliary personnel;Total;479,176
1.2) Labour expenditure of technical and auxiliary personnel;Public Administration;155,370
1.2) Labour expenditure of technical and auxiliary personnel;Higher Education;91,894
1.2) Labour expenditure of technical and auxiliary personnel;Companies;229,734
1.2) Labour expenditure of technical and auxiliary personnel;NPPI;2,178
1.3) Other current expenditure;Total;1,026,833
1.3) Other current expenditure;Public Administration;313,348
1.3) Other current expenditure;Higher Education;130,437
1.3) Other current expenditure;Companies;578,032
1.3) Other current expenditure;NPPI;5,017
2) By type of expenditure: Capital expenditure;Total;213,838
2) By type of expenditure: Capital expenditure;Public Administration;52,362
2) By type of expenditure: Capital expenditure;Higher Education;57,827
2) By type of expenditure: Capital expenditure;Companies;103,159
2) By type of expenditure: Capital expenditure;NPPI;490
2.1) Land and buildings;Total;28,577
2.1) Land and buildings;Public Administration;5,863
2.1) Land and buildings;Higher Education;11,615
2.1) Land and buildings;Companies;10,889
2.1) Land and buildings;NPPI;210
2.2) Equipment and tools;Total;146,829
2.2) Equipment and tools;Public Administration;45,051
2.2) Equipment and tools;Higher Education;42,322
2.2) Equipment and tools;Companies;59,204
2.2) Equipment and tools;NPPI;253
2.3) Acquisition of specific R&D software;Total;7,338
2.3) Acquisition of specific R&D software;Public Administration;1,354
2.3) Acquisition of specific R&D software;Higher Education;339
2.3) Acquisition of specific R&D software;Companies;5,623
2.3) Acquisition of specific R&D software;NPPI;21
2.4) Other R&D-specific IP products;Total;31,094
2.4) Other R&D-specific IP products;Public Administration;94
2.4) Other R&D-specific IP products;Higher Education;3,552
2.4) Other R&D-specific IP products;Companies;27,442
2.4) Other R&D-specific IP products;NPPI;6
1.1) By origin of funds: Own funds;Total;1,107,216
1.1) By origin of funds: Own funds;Public Administration;99,226
1.1) By origin of funds: Own funds;Higher Education;117,157
1.1) By origin of funds: Own funds;Companies;887,527
1.1) By origin of funds: Own funds;NPPI;3,306
1.2) By origin of funds: Funds from the Business sector;Total;258,957
1.2) By origin of funds: Funds from the Business sector;Public Administration;69,960
1.2) By origin of funds: Funds from the Business sector;Higher Education;42,038
1.2) By origin of funds: Funds from the Business sector;Companies;143,903
1.2) By origin of funds: Funds from the Business sector;NPPI;3,055
1.3) By origin of funds: Funds from the Public Administration sector;Total;1,065,003
1.3) By origin of funds: Funds from the Public Administration sector;Public Administration;512,667
1.3) By origin of funds: Funds from the Public Administration sector;Higher Education;424,208
1.3) By origin of funds: Funds from the Public Administration sector;Companies;126,546
1.3) By origin of funds: Funds from the Public Administration sector;NPPI;1,582
1.4) By origin of funds: Funds from the Higher Education sector;Total;5,113
1.4) By origin of funds: Funds from the Higher Education sector;Public Administration;1,150
1.4) By origin of funds: Funds from the Higher Education sector;Higher Education;3,842
1.4) By origin of funds: Funds from the Higher Education sector;Companies;94
1.4) By origin of funds: Funds from the Higher Education sector;NPPI;27
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Total;51,237
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Public Administration;20,158
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Higher Education;17,468
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Companies;12,623
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;NPPI;988
1.6) By origin of funds: Funds from the rest of the world;Total;261,103
1.6) By origin of funds: Funds from the rest of the world;Public Administration;86,839
1.6) By origin of funds: Funds from the rest of the world;Higher Education;59,252
1.6) By origin of funds: Funds from the rest of the world;Companies;112,652
1.6) By origin of funds: Funds from the rest of the world;NPPI;2,359
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Total;177,658
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Public Administration;38,288
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Higher Education;1,802
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Companies;137,432
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);NPPI;135
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Total;124,133
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Public Administration;34,179
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Higher Education;1,692
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Companies;88,127
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;NPPI;134
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Total;53,525
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Public Administration;4,109
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Higher Education;110
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Companies;49,305
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;NPPI;1
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Total;45.9
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Public Administration;65.5
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Higher Education;50.0
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Companies;43.7
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to capital;NPPI;73.3
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Total;15.5
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Public Administration;10.3
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Higher Education;11.8
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Companies;16.2
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;NPPI;6.7
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Total;25.8
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Public Administration;47.4
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Higher Education;33.8
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Companies;23.7
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;NPPI;20.0
% Units that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Total;15.7
% Units that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Public Administration;21.6
% Units that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Higher Education;33.8
% Units that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Companies;14.5
% Units that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;NPPI;6.7
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Total;20.1
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Public Administration;27.6
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Higher Education;44.1
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Companies;18.1
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;NPPI;40.0
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Total;21.1
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Public Administration;29.3
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Higher Education;41.2
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Companies;19.6
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;NPPI;6.7
% Units that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Total;17.9
% Units that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Public Administration;7.8
% Units that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Higher Education;10.3
% Units that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Companies;19.1
% Units that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;NPPI;13.3
% Units that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Total;49.3
% Units that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Public Administration;47.4
% Units that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Higher Education;44.1
% Units that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Companies;49.8
% Units that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;NPPI;33.3
% Units that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Total;59.5
% Units that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Public Administration;59.5
% Units that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Higher Education;60.3
% Units that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Companies;59.4
% Units that consider the following obstacles to the development of biotechnologies as very important: Time/cost;NPPI;73.3
% Units that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Total;22.1
% Units that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Public Administration;20.7
% Units that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Higher Education;17.6
% Units that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Companies;22.3
% Units that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;NPPI;33.3